Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-025-60317-z
Affiliations:
2
Authors:
14
Go to article
Institutions Authors Share
Shanghai Changzheng Hospital, SMMU, China
13.000000
13.000000
 0.93
3D Medicines Inc., China
1.000000
 0.07
Interested in Oncology and Carcinogenesis?